BiotechTube

ALN-TTRSC02 + Sterile Normal Saline (0.9% NaCl)

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Transthyretin-mediated Amyloidosis (ATTR Amyloidosis)

Conditions

Transthyretin-mediated Amyloidosis (ATTR Amyloidosis)

Trial Timeline

Jun 7, 2016 → Jan 12, 2018

NCT ID
NCT02797847

About ALN-TTRSC02 + Sterile Normal Saline (0.9% NaCl)

ALN-TTRSC02 + Sterile Normal Saline (0.9% NaCl) is a phase 1 stage product being developed by Alnylam Pharmaceuticals for Transthyretin-mediated Amyloidosis (ATTR Amyloidosis). The current trial status is completed. This product is registered under clinical trial identifier NCT02797847. Target conditions include Transthyretin-mediated Amyloidosis (ATTR Amyloidosis).

What happened to similar drugs?

0 of 5 similar drugs in Transthyretin-mediated Amyloidosis (ATTR Amyloidosis) were approved

Approved (0) Terminated (0) Active (5)
🔄Eplontersen + PlaceboAstraZenecaPhase 3
🔄EplontersenAstraZenecaPhase 3
🔄Nucresiran + VutrisiranAlnylam PharmaceuticalsPhase 3
🔄EplontersenIonis PharmaceuticalsPhase 3
🔄Inotersen + EplontersenIonis PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02797847Phase 1Completed

Competing Products

9 competing products in Transthyretin-mediated Amyloidosis (ATTR Amyloidosis)

See all competitors
ProductCompanyStageHype Score
Eplontersen Solution for InjectionAstraZenecaPhase 1
29
Eplontersen + PlaceboAstraZenecaPhase 3
44
EplontersenAstraZenecaPhase 3
47
PatisiranAlnylam PharmaceuticalsPre-clinical
23
PatisiranAlnylam PharmaceuticalsPre-clinical
23
Nucresiran + VutrisiranAlnylam PharmaceuticalsPhase 3
44
ALN-TTRSC04 + PlaceboAlnylam PharmaceuticalsPhase 1
26
EplontersenIonis PharmaceuticalsPhase 3
41
Inotersen + EplontersenIonis PharmaceuticalsPhase 3
37